Toggle Main Menu Toggle Search

Open Access padlockePrints

123I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort

Lookup NU author(s): Dr Joseph Kane, Dr Gemma Roberts, Dr George Petrides, Dr James LloydORCiD, Professor John O'Brien, Professor Alan ThomasORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2019 Objective: To determine the utility of 123I-metaiodobenzylguanidine cardiac scintigraphy (MIBG), and optimum heart: mediastinum ratio (HMR) for differentiating dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) in a clinically representative population, comparing findings with those of 123I-2β -carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT) SPECT. Methods: We recruited subjects with probable DLB (n = 17) and probable AD (n = 16) from clinical services. Each participant underwent clinical examination, cardiac MIBG scintigraphy and FP-CIT SPECT. Diagnosis was made on the basis of clinical symptoms using validated criteria. Cardiac MIBG uptake was measured by the planar HMR, blind to clinical diagnosis, with values below a cut-off taken from a previous study (<2.2 at four hours) defining scans as abnormal. FP-CIT scans were blindly rated according to a visual rating scale. Results: MIBG had a sensitivity, specificity and overall accuracy of 71%, 81% and 76% for distinguishing DLB from AD. FP-CIT demonstrated a sensitivity, specificity and accuracy of 88%, 75% and 82%. Using a lower HMR cut-off to distinguish between abnormal and normal MIBG scans improved the accuracy of MIBG, raising specificity (100%) and overall accuracy (85%) without compromising sensitivity (71%). Neither prescription of potentially interfering medications, nor a history of myocardial infarction (MI), had a significant effect on HMR. Conclusion: We found that MIBG did not demonstrate superior sensitivity and overall accuracy to FP-CIT. HMR cut-off influences biomarker utility, and clinical and Caucasian populations may require a lower cut-off than those reported elsewhere. Future MIBG studies should include clinically representative cohorts as neither medications nor previous MI appear to influence HMR.

Publication metadata

Author(s): Kane JPM, Roberts G, Petrides GS, Lloyd JJ, O'Brien JT, Thomas AJ

Publication type: Article

Publication status: Published

Journal: Parkinsonism and Related Disorders

Year: 2019

Volume: 62

Pages: 79-84

Print publication date: 01/05/2019

Online publication date: 26/01/2019

Acceptance date: 25/01/2019

ISSN (print): 1353-8020

ISSN (electronic): 1873-5126

Publisher: Elsevier Ltd


DOI: 10.1016/j.parkreldis.2019.01.024


Altmetrics provided by Altmetric